Last reviewed · How we verify
NCT03795038: DIAMOND-2018
Comparison of the Plasma Lipoprotein Apheresis Systems DIAMED and MONET vs. the Whole Blood Apheresis System DALI
NA trial testing Lipoprotein Apheresis MONET and DALI in Hypercholesterolemia, Familial in 20 participants. Completed in 25 May 2021.
25 May 2021
Quick facts
| Lead sponsor | Fresenius Medical Care Deutschland GmbH |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 28 December 2018 |
| Primary completion | 25 May 2021 |
| Estimated completion | 25 May 2021 |
| Sites | 2 locations across Germany |
Drugs / interventions tested
- Lipoprotein Apheresis MONET and DALI
- Lipoprotein Apheresis DIAMED and DALI
Conditions studied
- Hypercholesterolemia, Familial — all drugs for Hypercholesterolemia, Familial →
- Dyslipidemias — all drugs for Dyslipidemias →
- Cardiovascular Diseases — all drugs for Cardiovascular Diseases →
Sponsor
Fresenius Medical Care Deutschland GmbH — full company profile →
Who can join
18 and older, any sex, with Hypercholesterolemia, Familial or Dyslipidemias. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The clinical Investigation will be performed to compare the safety and effectiveness of the CE certified and established lipoprotein apheresis systems MONET vs. DALI and DIAMED vs. DALI for optimizing the individual therapy of patients with severe dyslipidemia using established and novel efficacy parameters.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03795038
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hypercholesterolemia, Familial
Currently open trials in the same condition.
- NCT04073797 — PET Imaging of Inflammation and Lipid Lowering Study · NA · recruiting
- NCT03989167 — Clinical Decision Support for Familial Hypercholesterolemia · NA · recruiting
- NCT04656028 — Genetic Testing and Motivational Counseling for FH · NA · active not recruiting
Other Fresenius Medical Care Deutschland GmbH trials
Trials by the same sponsor.
- NCT06236984 — Retrospective Data Analysis of CKRT (Continuous Kidney Replacement Therapy) Treatments in Adult Mode With multiFiltrateP · completed
- NCT05441020 — Development, Feasibility Testing and Validation of a Survey Set to Measure Patient-Reported Outcomes Among Hemodialysis · completed
- NCT05315817 — Safety and Performance Evaluation of multiPlus Dialysate During CRRT · NA · terminated
- NCT05142501 — Observation of the Immune Response After COVID-19 Additional Vaccine Doses in Chronic Patients in Hemodialysis Therapy · terminated
- NCT04871893 — Safety and Efficacy Evaluation of CO2 Removal in Combination With Continuous Veno-Venous Hemodialysis/Hemodiafiltration · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03795038 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fresenius Medical Care Deutschland GmbH
- Last refreshed: 28 July 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03795038.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing